Phaseline

Targets › CTLA4

CTLA4 (Cytotoxic T-lymphocyte protein 4): drug programs, companies and trials

71 programs from 59 companies in 534 trials: 353 Phase 2, 117 Phase 1, 60 Phase 3, 4 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.

Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. (UniProt, P16410)

Open in Phaseline: the race on CTLA4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
AkesoCadonilimab (AK104)
Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor
PDCD1, CTLA4Phase 3Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) …Nov 2026
Shandong Cancer Hospital and InstituteIparomlimab
CTLA-4 inhibitor
CTLA4Phase 3Local Advanced Rectal Cancer; Rectal Malignant Neoplasms; Cervical CancerNov 2026
OncoC4ONC-392 (Gotistobart)
anti-CTLA4 monoclonal antibody
CTLA4Phase 3Non Small Cell Lung Cancer; Ovarian Cancer; Metastatic Castration-resistant Prostate CancerNov 2026
AstraZenecaTremelimumab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 3Small Cell Lung Cancer; Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Non Small Cell Lung Carcinoma NSCLC …Nov 2026
AstraZenecaVolrustomig (MEDI5752)
CTLA-4/PD-1 bispecific antibody
CTLA4, PDCD1, TIGITPhase 3Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma …Jan 2027
Bristol-Myers SquibbIpilimumab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 3Urothelial Cancer; Renal Cell Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer …Feb 2027
Merck & Co. (MSD)Quavonlimab
CTLA-4 inhibitor
CTLA4Phase 3Carcinoma, Renal CellApr 2027
Tongji HospitalIparomlimab and Tuvonralimab (QL1706)
Bispecific antibody targeting PD-1 and CTLA-4
CTLA4, PDCD1Phase 3Ovarian Clear Cell Carcinoma; Resectable Hepatocellular Carcinoma With High Risk of RecurrenceJun 2027
Innovent Biologics (Suzhou)IBI310
CTLA-4 inhibitor
CTLA4Phase 3MSI-HApr 2028
Summit TherapeuticsIvonescimab Dose 1
TIGIT inhibitor
TIGIT, CTLA4Phase 3Non-Small Cell Lung Cancer; Metastatic Urothelial CarcinomaApr 2028
UNICANCERReduced dose intensity of IO
Anti-PD-1, anti-PD-L1, or anti-CTLA-4 checkpoint inhibitor
PDCD1, CD274, CTLA4Phase 3Lung Cancer MetastaticMay 2029
Xijing HospitalIBI-310
CTLA-4 inhibitor
CTLA4Phase 2MSI-H/dMMR Locally Advanced Rectal AdenocarcinomaNov 2026
Sichuan Baili PharmaceuticalSI-B003
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer …Nov 2026
Hebei Medical University Fourth HospitalIparomlimab
CTLA-4 inhibitor
CTLA4, TIGITPhase 2Esophageal Squamous Cell Carcinoma (ESCC); AFP Gastric or Gastroesophageal Junction Adenocarcinoma; Colon CancerDec 2026
Jiang LongAdebelimab
CTLA-4 monoclonal antibody
CTLA4Phase 2Pancreatic Cancer Metastatic to LiverDec 2026
Sir Run Run Shaw HospitalAiparolitoworixureli injection
PD-1/CTLA-4 bispecific monoclonal antibody; dual checkpoint inhibitor blocking PD-1 and CT
PDCD1, CTLA4Phase 2Rectal CancerDec 2026
Ruijin HospitalIparomlimab and Tuvonralimab (QL1706)
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Gastric AdenocarcinomaDec 2026
First Affiliated Hospital of Zhejiang UniversityPD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection)
PD-1/CTLA-4 dual checkpoint inhibitor antibody
PDCD1, CTLA4Phase 2Bile Duct CarcinomaDec 2026
Shandong Provincial HospitalQL1706 (Iparomlimab and Tuvonralimab)
Combination of PD-1 inhibitor (Iparomlimab) and CTLA-4 inhibitor (Tuvonralimab)
PDCD1, CTLA4Phase 2Locally Advanced Resectable Esophageal Squamous Cell Carcinoma; Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaDec 2026
Second Affiliated Hospital, Zhejiang University, School of MedicinePD-1/VEGF dual antibody
PD-1 inhibitor and anti-VEGF antibody
PDCD1, VEGFA, CTLA4Phase 2GlioblastomaJan 2027
Zhongnan HospitalTuvonralimab (QL1706)
CTLA-4 inhibitor
CTLA4Phase 2Rectal Cancer PatientsJan 2027
Peking University Cancer Hospital & InstituteQL1706
Anti-PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Esophageal Squamous Cell CarcinomaMar 2027
Sun Yat-sen UniversityIparomlimab and Tuvonralimab (QL1706)
Dual PD-1/CTLA-4 combination antibody
CTLA4, PDCD1Phase 2Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer; Bone and Soft Tissue Tumors; BRAF V600 Colorectal Cancer; Hepatocellular Carcinoma (HCC) …Apr 2027
Tianjin Medical University Cancer Institute and Hospitallparomlimab and Tuvonralimab Injection (QL1706)
Anti-PD-1/CTLA-4 combined antibody
PDCD1, CTLA4Phase 2Endometrial Adenocarcinoma; Metastatic Pancreatic Cancer; HCC; Breast CancerApr 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAitua Combination Antibody (QL1706)
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2High-grade Serous Ovarian Cancer (HGSOC)May 2027
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universitytirilizumab
CTLA-4 inhibitor
CTLA4Phase 2Locally Advanced Head and Neck Squamous Cell CarcinomaJun 2027
Tianjin Medical University Second HospitalTagitanlimab
anti-CTLA-4 monoclonal antibody
CTLA4Phase 2Prostate Cancer (Adenocarcinoma)Jun 2027
Xijing HospitalIparomlimab/Tuvonralimab (QL1706)
Bispecific antibody targeting PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Locally Advanced Cervical CancerJul 2027
MacroGenicsLorigerlimab
Bispecific DART protein binding PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic AdenocarcinomaJul 2027
Ruijin HospitalApalulizumab
Dual-function antibody targeting both PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Pancreatic Adenocarcinoma Locally AdvancedAug 2027
Ruijin HospitalDual-Function Antibody PD-1/CTLA-4 (Apalulizumab)
Bispecific antibody targeting PD-1 and CTLA-4 immune checkpoints
PDCD1, CTLA4Phase 2Pancreatic Adenocarcinoma Locally AdvancedAug 2027
The First Affiliated Hospital of Zhengzhou Universitycadonilizumab
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Esophageal Squamous Cell CarcinomaAug 2027
AgenusBotensilimab
Anti-CTLA-4 monoclonal antibody
CTLA4Phase 2Advanced Melanoma; Metastatic Colorectal Cancer; Gastric Cancer; Colorectal Cancer Metastatic …Sep 2027
Yongxu JiaIparomlimab and Tuvonralimab Injection (QL1706)
CTLA-4 and PD-1 dual checkpoint inhibitor
CTLA4, PD-1Phase 2Gastroesophageal Junction AdenocarcinomaSep 2027
Tianjin Medical University Cancer Institute and HospitalIparomlimab
PD-1 and CTLA-4 inhibitor
PDCD1, CTLA4Phase 2Esophageal CancerSep 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyIparomlimab and Tuvonralimab (QL1706)
PD-1 and CTLA-4 dual checkpoint inhibitor
PDCD1, CTLA4Phase 2HCC - Hepatocellular CarcinomaOct 2027
Qilu Hospital of Shandong UniversityIparomlimab and Tuvonralimab (QL1706)
Dual CTLA-4 and PD-1 inhibitor
CTLA4, PD-1Phase 2HER2 NegativeOct 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesIparomlimab/Tuvonralimab
Bifunctional mabpair product of anti-PD-1 and anti-CTLA-4 antibodies
PDCD1, CTLA4Phase 2LOCALLY ADVANCED CERVICAL CANCERSNov 2027
Lei LiuIvonescimab
Bispecific antibody targeting PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Head and Neck Squamous Cell CarcinomaDec 2027
Jiangsu Cancer Institute & HospitalTuvonralimab
CTLA-4 inhibitor
CTLA4Phase 2NSCLCDec 2027
Nanfang Hospital, Southern Medical UniversityIparomlimab and Tuvonralimab Injection (QL1706)
PD-1 and CTLA-4 dual inhibitor
PDCD1, CTLA4Phase 2Hepatecellular CarcinomaDec 2027
Innovent Biopharmaceutical Technology (Hangzhou)IBI310
CTLA-4 inhibitor
CTLA4Phase 2Hepatocellular Carcinoma (HCC); Neuroendocrine Neoplasm; Gastric CancerDec 2027
The First Affiliated Hospital of Xiamen UniversityIparomlimab/Tuvorlimab (QL-1706)
CTLA-4 inhibitor
CTLA4Phase 2Locally Advanced Nasopharyngeal CarcinomaDec 2027
Shanghai Zhongshan HospitalIparomlimab and Tuvonralimab (QL1706)
Bifunctional monoclonal antibody composed of PD-1 inhibitor (IgG4) and CTLA-4 inhibitor (I
PDCD1, CTLA4Phase 2Biliary Tract Cancer (BTC)Jun 2028
Shanghai Pulmonary Hospital, Shanghai, ChinaIBI310
anti-CTLA-4 antibody
CTLA4Phase 2NSCLC Stage IIJun 2028
Second Affiliated Hospital of Nanchang UniversityTuvonralimab
CTLA-4 inhibitor
CTLA4Phase 2CancerJun 2028
Changhai HospitalQL1706
Dual PD-1/CTLA-4 antibody
PDCD1, CTLA4Phase 2MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706Aug 2028
Changhai Hospitaliparomlimab
CTLA-4 inhibitor
CTLA4Phase 2MSS-type Low Rectal Cancer,Neoadjuvant Chemoradiotherapy, QL1706Aug 2028
Tianjin Medical University Cancer Institute and HospitalIparomlimab/Tuvonralimab
CTLA-4 and PD-1 inhibitor combination
CTLA4, PD-1Phase 2HCC - Hepatocellular CarcinomaAug 2028
Obstetrics & Gynecology Hospital of Fudan UniversityIvonescimab
TIGIT inhibitor with bispecific antibody targeting TIGIT and PD-1
PDCD1, CTLA4Phase 2Cervical CancersAug 2028
Second Affiliated Hospital of Guangzhou Medical UniversityCTLA-4 antibody
CTLA-4 immune checkpoint inhibitor
CTLA4Phase 2Lung CancerDec 2028
West China HospitalIvonescimab
PD-1 and CTLA-4 dual inhibitor
PD-1, CTLA4Phase 2Head and Neck Squamous Cell CarcinomaDec 2028
Kong Fanmingattilizumab
CTLA-4 inhibitor
CTLA4Phase 2Non-Small Cell Lung CancerDec 2028
Second Affiliated Hospital of Guangzhou Medical UniversityPD-1/PD-L1/CTLA-4 inhibitors
PD-1, PD-L1, and CTLA-4 checkpoint inhibitors
PDCD1, CD274, CTLA4Phase 2Head/Neck NeoplasmJan 2029
Sun Yat-sen UniversityIpromlimab
CTLA-4 inhibitor
CTLA4Phase 2Locally Advanced, ResectableJun 2029
Fujian Cancer HospitalTuvonralimab
CTLA-4 inhibitor
CTLA4Phase 2Locally Advanced Cervical CancerSep 2029
Immune Oncology Research InstituteBotensilimab
Fc-engineered monoclonal antibody targeting CTLA-4
CTLA4Phase 2Non-small Cell Lung CancerApr 2030
Innovent Biopharmaceutical Technology (Hangzhou)Ipilimumab (N01)
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 2Resectable Gastric/Gastroesophageal Junction AdenocarcinomaDec 2031
Xencorvudalimab (XmAb20717)
Bispecific monoclonal antibody targeting CTLA-4 and TIGIT
CTLA4, TIGITPhase 2Ovarian Cancer–
Shanghai Zhongshan Hospitalcardonilizumab
PD-1 and CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 1Biliary Tract CancerDec 2026
Shanghai Henlius BiotechHLX13
CTLA-4 inhibitor (anti-CTLA-4 monoclonal antibody biosimilar)
CTLA4Phase 1Hepatocellular Carcinoma (HCC)Dec 2026
Fudan UniversityIBI110
LAG-3 inhibitor
CTLA4Phase 1Head and Neck CancerDec 2026
Memorial Sloan Kettering Cancer CenterAntithymocyte globulin (ATG)
Polyclonal antibody targeting T lymphocytes; immunosuppressant
CTLA4, CD2, CD3, CD4, CD8Phase 1Myeloid Diseases; Hematologic MalignanciesMay 2027
AdageneADG126
anti-CTLA-4 monoclonal antibody
CTLA4Phase 1Advanced/Metastatic Solid Tumors; Locally Advanced Colorectal CancerJun 2027
ImmunoGenesisZalifrelimab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 1Metastatic Prostate Cancer; Metastatic Soft Tissue Sarcoma; Diffuse Intrinsic Pontine GliomaOct 2027
Revolution MedicinesIvonescimab
PD-1 and CTLA-4 dual antagonist
PD-1, CTLA4Phase 1Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma …May 2029
BioNTech SEBNT316
anti-CTLA-4 antibody
CTLA4Phase 1Non-Small Cell Lung CancerFeb 2030
InxMed (Shanghai)Erfonrilimab (KN046)
Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor
CTLA4, CD274Phase 1Pancreatic Cancer; Digestive System Cancers; HER2-positive Locally Advanced Resectable Gastric Cancer–
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.IMM27M
Humanized Fc-engineered anti-CTLA-4 antibody
CTLA4Phase 1Advanced Solid Tumors–
NelumZalifrelimab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 1Pancreatic Ductal Adenocarcinoma–

Conditions

Hepatocellular Carcinoma (19) Melanoma (12) Colorectal Cancer (11) Non-Small Cell Lung Cancer (10) Hepatocellular Carcinoma (HCC) (10) Non Small Cell Lung Cancer (9) Cervical Cancer (8) Head and Neck Squamous Cell Carcinoma (7) Non-small Cell Lung Cancer (7) Breast Cancer (6) Pancreatic Cancer (6) Metastatic Colorectal Cancer (6)

Modalities

mixed (28), antibody (26), small molecule (10), protein or peptide (1)

Companies

Tianjin Medical University Cancer Institute and Hospital (3) Ruijin Hospital (3) AstraZeneca (2) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) Innovent Biopharmaceutical Technology (Hangzhou) (2) Shanghai Zhongshan Hospital (2) Second Affiliated Hospital of Guangzhou Medical University (2) Changhai Hospital (2) Xijing Hospital (2) Sun Yat-sen University (2) Shandong Cancer Hospital and Institute (1) Sichuan Baili Pharmaceutical (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Summit Therapeutics (1) Revolution Medicines (1) OncoC4 (1) Yongxu Jia (1) Bristol-Myers Squibb (1) Akeso (1) InxMed (Shanghai) (1)

Related targets

PDCD1 (30) PD-1 (5) TIGIT (4) CD274 (3) CD2 (1) CD3 (1) CD4 (1) CD8 (1) GLP1R (1) ATP4A (1) ATP4B (1) FKBP1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.